About
Technology
Issues
FAQ
Links
Official Page
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3
MEASURE
3 Study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.